Rimegepant

Last updated

Rimegepant
Rimegepant.svg
Clinical data
Trade names Nurtec ODT, Vydura
Other namesBHV-3000, BMS-927711
AHFS/Drugs.com Monograph
MedlinePlus a620031
License data
Pregnancy
category
Routes of
administration 		By mouth
Drug class Calcitonin gene-related peptide receptor antagonist
ATC code
Legal status
Legal status
Identifiers
  • [(5S,6S,9R)-5-Amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl] 4-(2-oxo-3H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C28H28F2N6O3
Molar mass 534.568 g·mol−1
3D model (JSmol)
  • N[C@@H]1c2cccnc2[C@H](OC(=O)N2CCC(n3c(=O)[nH]c4ncccc43)CC2)CC[C@H]1c1cccc(F)c1F
  • InChI=1S/C28H28F2N6O3/c29-20-6-1-4-17(23(20)30)18-8-9-22(25-19(24(18)31)5-2-12-32-25)39-28(38)35-14-10-16(11-15-35)36-21-7-3-13-33-26(21)34-27(36)37/h1-7,12-13,16,18,22,24H,8-11,14-15,31H2,(H,33,34,37)/t18-,22+,24-/m0/s1
  • Key:KRNAOFGYEFKHPB-ANJVHQHFSA-N

Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. [8] [10] It is taken by mouth to dissolve on or under the tongue. [8] It works by blocking CGRP receptors. [11]

Contents

In the United States, rimegepant was approved for treating acute migraine in February 2020, [12] and its approval was extended to preventing episodic migraine in June 2021. [8] It is produced and marketed by Pfizer. [13] In March 2021, rimegepant was approved for medical use in the United Arab Emirates and in Israel. [14] [15] It was approved for medical use in Canada in December 2023. [4] In the United Kingdom, rimegepant is approved by NICE for the prophylaxis and treatment of acute migraine in adults. [16]

Medical uses

Rimegepant is indicated for the treatment of acute migraine with or without aura in adults and for the preventative treatment of episodic migraine in adults. [8] [10] [9]

Mechanism of action

Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist. [11]

History

Rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020. [12] [17] Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches. [10]

Society and culture

On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine. [18] The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC. [18] Rimegepant was approved for medical use in the European Union in April 2022. [9] [19]

Related Research Articles

<span class="mw-page-title-main">Gemtuzumab ozogamicin</span> Pharmaceutical drug

Gemtuzumab ozogamicin, sold under the brand name Mylotarg®, is an antibody-drug conjugate that is used to treat acute myeloid leukemia (AML).

<span class="mw-page-title-main">Tremelimumab</span> Monoclonal antibody

Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody used for the treatment of hepatocellular carcinoma. Tremelimumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

<span class="mw-page-title-main">Lasmiditan</span> Chemical compound

Lasmiditan, sold under the brand name Reyvow, is a medication used for the acute treatment of migraine with or without aura in adults. It is not useful for prevention. It is taken by mouth.

<span class="mw-page-title-main">Ruxolitinib</span> Medication

Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative neoplasm that affects the bone marrow; polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease. Ruxolitinib is a Janus kinase inhibitor. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in the world, under the brand name Jakavi.

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drugs that act as antagonists of the calcitonin gene-related peptide receptor (CGRPR).

<span class="mw-page-title-main">Sacituzumab govitecan</span> Antibody-drug conjugate

Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.

<span class="mw-page-title-main">Difelikefalin</span> Chemical compound

Difelikefalin, sold under the brand name Korsuva, is an opioid peptide used for the treatment of moderate to severe itch. It acts as a peripherally-restricted, highly selective agonist of the κ-opioid receptor (KOR).

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion every 3 months.

<span class="mw-page-title-main">Ivosidenib</span> Anti-cancer medication

Ivosidenib, sold under the brand name Tibsovo, is an anti-cancer medication for the treatment of acute myeloid leukemia (AML) and cholangiocarcinoma. It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. Ivosidenib is an isocitrate dehydrogenase-1 inhibitor that works by decreasing abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG), leading to differentiation of malignant cells.

<span class="mw-page-title-main">Zanubrutinib</span> Chemical compound

Zanubrutinib, sold under the brand name Brukinsa, is an anticancer medication used for the treatment of mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL). Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It is given by mouth.

Givosiran, sold under the brand name Givlaari, is a medication used for the treatment of adults with acute hepatic porphyria. Givosiran is a small interfering RNA (siRNA) directed towards delta-aminolevulinate synthase 1 (ALAS1), an important enzyme in the production of heme.

<span class="mw-page-title-main">Abrocitinib</span> Chemical compound

Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth.

<span class="mw-page-title-main">Pemigatinib</span> Pharmaceutical drug

Pemigatinib, sold under the brand name Pemazyre, is an anti-cancer medication used for the treatment of bile duct cancer (cholangiocarcinoma). Pemigatinib works by blocking FGFR2 in tumor cells to prevent them from growing and spreading.

Tafasitamab, sold under the brand name Monjuvi, is a medication used in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Somapacitan, sold under the brand name Sogroya, is a growth hormone medication. Somapacitan is a human growth hormone analog. Somapacitan-beco is produced in Escherichia coli by recombinant DNA technology.

<span class="mw-page-title-main">Vericiguat</span> Medication

Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and hospitalization in certain patients with heart failure after a recent acute decompensation event. It is taken by mouth. Vericiguat is a soluble guanylate cyclase (sGC) stimulator.

<span class="mw-page-title-main">Asciminib</span> Chemical compound

Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia. Asciminib is a protein kinase inhibitor.

Somatrogon, sold under the brand name Ngenla, is a medication for the treatment of growth hormone deficiency. Somatrogon is a glycosylated protein constructed from human growth hormone and a small part of human chorionic gonadotropin which is appended to both the N-terminal and C-terminal. Somatrogon is a human growth hormone analog.

Spesolimab, sold under the brand name Spevigo, is a monoclonal antibody used for the treatment of generalized pustular psoriasis (GPP). It is an interleukin-36 receptor (IL-36R) antagonist. It is given via injection into a vein.

References

  1. 1 2 "Nurtec ODT". Therapeutic Goods Administration (TGA). 8 August 2023. Archived from the original on 11 October 2023. Retrieved 10 September 2023.
  2. ↑ https://www.tga.gov.au/resources/auspar/auspar-nurtec-odt [ bare URL ]
  3. ↑ "Nurtec ODT (Pfizer Australia Pty Ltd)". Therapeutic Goods Administration (TGA). 22 August 2023. Archived from the original on 11 September 2023. Retrieved 10 September 2023.
  4. 1 2 "Archived copy" (PDF). Archived (PDF) from the original on 3 March 2024. Retrieved 10 March 2024.{{cite web}}: CS1 maint: archived copy as title (link)
  5. ↑ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-02-28]". Health Canada . 28 February 2024. Archived from the original on 2 March 2024. Retrieved 2 March 2024.
  6. ↑ "Details for: Nurtec ODT". Health Canada . 1 December 2023. Archived from the original on 3 March 2024. Retrieved 3 March 2024.
  7. ↑ "Summary Basis of Decision for Nurtec ODT". Drug and Health Products Portal. 1 September 2012. Retrieved 23 July 2024.
  8. 1 2 3 4 5 "Nurtec ODT - rimegepant sulfate tablet, orally disintegrating". DailyMed. 19 February 2020. Archived from the original on 28 November 2020. Retrieved 19 March 2020.
  9. 1 2 3 "Vydura EPAR". European Medicines Agency (EMA). 22 February 2022. Archived from the original on 16 October 2022. Retrieved 11 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. 1 2 3 "Drug Trials Snapshots: Nurtec ODT". U.S. Food and Drug Administration (FDA). 27 February 2020. Archived from the original on 1 October 2020. Retrieved 19 March 2020.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  11. 1 2 Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). "New therapeutic approaches for the prevention and treatment of migraine". The Lancet. Neurology. 14 (10): 1010–1022. doi:10.1016/S1474-4422(15)00198-2. PMID   26376968. S2CID   26523013.
  12. 1 2 "Drug Approval Package: Nurtec ODT". U.S. Food and Drug Administration (FDA). 26 March 2020. Archived from the original on 27 December 2021. Retrieved 16 October 2022.
  13. ↑ "Pfizer Completes Acquisition of Biohaven Pharmaceuticals". Pfizer (Press release). 3 October 2022. Archived from the original on 5 October 2022. Retrieved 16 October 2022.
  14. ↑ "Biohaven Pharma's Nurtec ODT Approved In Israel For Acute Treatment Of Migraine". StreetInsider.com. Archived from the original on 3 June 2021. Retrieved 3 June 2021.
  15. ↑ "Biohaven's Nurtec ODT Approved In United Arab Emirates For Acute Treatment Of Migraine". Biohaven Pharmaceuticals (Press release). Archived from the original on 11 March 2021. Retrieved 3 June 2021.
  16. ↑ "Overview | Rimegepant for treating migraine | Guidance | NICE". www.nice.org.uk. 18 October 2023. Retrieved 26 July 2024.
  17. ↑ "Biohaven's Nurtec ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults" (Press release). Biohaven Pharmaceuticals Holding Company Ltd. 27 February 2020. Archived from the original on 26 July 2021. Retrieved 28 February 2020– via PR Newswire.
  18. 1 2 "Vydura: Pending EC decision". European Medicines Agency (EMA). 24 February 2022. Archived from the original on 27 February 2022. Retrieved 27 February 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  19. ↑ "Vydura Product information". Union Register of medicinal products. Archived from the original on 4 March 2023. Retrieved 3 March 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.